KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash from Financing Activities for 15 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 44.75% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 25.12% decrease, with the full-year FY2025 number at $9.1 million, down 25.12% from a year prior.
  • Cash from Financing Activities was $8.5 million for Q4 2025 at Supernus Pharmaceuticals, down from $21.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $80.2 million in Q1 2023 to a low of -$478.9 million in Q2 2023.
  • A 5-year average of -$25.9 million and a median of $2.0 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 6921.88% in 2021, then tumbled 21169.78% in 2023.
  • Supernus Pharmaceuticals' Cash from Financing Activities stood at -$136.7 million in 2021, then soared by 102.07% to $2.8 million in 2022, then crashed by 61.4% to $1.1 million in 2023, then soared by 439.38% to $5.9 million in 2024, then soared by 44.75% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash from Financing Activities are $8.5 million (Q4 2025), $21.1 million (Q3 2025), and $935000.0 (Q2 2025).